- Home
- CLOV vs KARD Comparison
CLOV vs KARD Comparison
Compare CLOV & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLOV | KARD |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CLOV | KARD |
|---|---|---|
| Price | $4.24 | $21.38 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.90 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 232.4K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.03 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,924,308,000.00 | N/A |
| Revenue This Year | $52.59 | N/A |
| Revenue Next Year | $15.37 | N/A |
| P/E Ratio | $42.55 | ★ N/A |
| Revenue Growth | ★ 40.34 | N/A |
| 52 Week Low | $1.58 | $19.41 |
| 52 Week High | $5.59 | $27.00 |
Technical Indicators
Market Signals| Indicator | CLOV | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 50.37 |
| Support Level | $4.09 | $19.61 |
| Resistance Level | $4.23 | $22.61 |
| Average True Range (ATR) | 0.13 | 1.36 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 52.24 | 45.80 |
Price Performance
Historical ComparisonAbout CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
About KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.